This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While the industry is seeing advances in alternative drugdeliverysystems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry. Compared to other dosage forms, tablets are simpler to manufacture, package, and transport.
Interestingly, over the past few years, drugdevelopers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
The more we know about where our meds are made (mostly not here) the less successful drug industry lobbying will be against lower-cost, imported medicines. In some cases, it’s as simple as a drug sold at a U.S. Walgreens is made in a manufacturing facility in one foreign country. Three countries have a hand in making it.
The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.
Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is administered by parenteral route.
Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drugdevelopers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. Currently, SHL Medical has four locations, in Switzerland, Taiwan, Sweden, and the US, with Taiwan being the main manufacturing location.
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. To boost the profitability of the drug at a later stage in its lifecycle, manufacturers may then consider changing the presentation to prefilled syringes. Lowering extractables levels .
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
The overall manufacturing of oligonucleotides involves the following steps. Owing to the incessant demand for oligonucleotide-based products, several small to mid-sized companies and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers. Accelerating Oligonucleotide Demand.
The companies allege Moderna’s vaccine uses their technology for a drug-deliverysystem without permission. Citing The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.
The VTT Technical Research Centre of Finland has addressed this issue by developing a fully recyclable, modular ECG patch constructed from VTT’s novel cellulose e-skin material. This device is designed such that the electronic components can be easily removed and reused. Behfar, senior scientist at VTT, in the news release.
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Want additional details on the pipeline?
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
Register for this free webinar to learn the best practices to successfully incorporate 2022 ISO 11608 methodology to mitigate risk and accelerate time to market in combination product development. The FDA’s Innovation Challenge 2 is centered on developing strategies to lower EtO emissions.
However, certain biological targets have long eluded drugdevelopment efforts. Advances in drug discovery and development technologies / platforms have increased the likelihood of targeting a number of the aforementioned types of biological targets.
Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Oral Protein / Peptide-based Drugs. Web: [link].
Conjugation with a Variety of Molecular Conjugates and Labels The combination of the conjugates / labels with molecules ( proteins, peptides, antibodies and small molecules ) is being used abundantly for several applications, ranging from therapeutics and diagnostics to isolation and characterization of drugdeliverysystems.
In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing. The company developingdrug product through such an intense process, use to consider container closure system only for packaging of the product. [1] Our Social Media Platform. Web: [link].
The six-page statement explains that “Brand drugmanufacturers may be harming generic competition through the improper listing of patents in the. But it is not always clear which types of patents are eligible for listing in the Orange Book.
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics. Web: [link].
“Reliable testing and certified personal protective equipment manufactured in the United States plays a key role in the pandemic response and getting our communities back to work. Vivera is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.
.
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. million adults in the United States.
Therapies such as dexamethasone drugdeliverysystem and vascular endothelial growth factor inhibitors have already pierced deeper into the market. The drug if approved will help minimize the use of unapproved repackaged IV bevacizumab from compounding pharmacists for retinal disease.
Koblitz — After years of silence from FDA on whether certain patents could be listed in the Orange Book, some manufacturers of drug and device combination products have had a rude awakening lately.
They offer several advantages over traditional drugdeliverysystems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. Prefilled syringes are syringes that come pre-filled with a specific dose of medication.
Challenges in Liposome Development and Manufacturing Although recent studies have shown encouraging advances in the liposome related therapeutics, there are several challenges that severely hinder development and manufacturing of liposomes.
Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017.
Several drugdevelopment trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. The need for quality When it comes to injectable medicine, achieving product sterility through aseptic manufacturing is of critical importance.
Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades. There are a variety of biologically derived therapeutics that are presently available / being developed.
Amidst the current initiatives to develop therapeutic interventions with improved bioavailability, nanoparticles have specifically captured the interest of researchers and drugdevelopers, given their ability to act as drug carriers for complex and highly promising therapeutics.
Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. Additionally, biopharmaceutical excipients act as bulking agents, antioxidants or preservatives.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality.
The key focus of these studies is on the development of anti-tumor therapeutics. You may also be interested in the following titles: Live Biotherapeutic Products and Microbiome Manufacturing Marke t Next Generation Complement Therapeutics Market Intranasal Therapeutics and DrugDeliverySystems Market. Web: [link].
Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. As a result, there is an evident increase in the demand for mRNA manufacturing capacity.
Unlocking the Path to Generic DrugDevelopment: A Freedom to Operate Analysis As a generic drugmanufacturer, navigating the complex landscape of biopharmaceutical development can be daunting. But what exactly is an FTO analysis, and why is it essential for your generic drug stability testing?
Amidst the ongoing initiatives to develop therapeutic interventions with improved bioavailability, lipid nanoparticle (LNPs) have specifically attracted the attention of researchers and drugdevelopers. Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.
A robust drug patent portfolio is not just an assetit’s a critical tool for success. As companies invest billions in research and development, protecting their innovations through strategic patent management has become more important than ever. These protect the core molecule or compound that gives a drug its therapeutic effect.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content